SPC Update

• Key issues of the Supplementary Protection Certificates
• SPC reform, e.g. unitary SPC
• ECJ referrals from Medeva to Genmab: context, background and interpretation
• Impact of the referrals on application practice and national court practice
• Pending referrals: what to expect from Teva v MSD (C-119/22)

Who should attend

In order to understand how to deal with supplementary protection certificates, one needs not only to understand the regulations but also the respective case-law. Thus the European Court of Justice has issued many important SPC decisions in the last few years: Medeva, Neurim, Actavis. The latest ones have raised more questions than have given answers. Our speaker, one of the leading SPC experts in Europe, will discuss the referrals with you. He will put the decisions in context and will show you the consequences for national court practice and for your application practice. Dr Brückner will also give some hints as to pending referrals and yet unsolved questions which might be the subject of future referrals. As 2024 might see a wide-reaching reform of the SPC law with, among others, a unitary SPC, our speaker will give you an overview and will explain to you what changes can be expected.

• You will be up to date with the case-law of the European Court of Justice on supplementary protection certificates
• You will get a better understanding of the articles of the regulations
• You will understand the impact of the unitary patent and the Unified Patent Court on supplementary protection certificates
• You will be up to date with regards to the EU SPC Reform